Rising prevalence of multiple sclerosis in Saudi Arabia, a descriptive study.


Journal

BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555

Informations de publication

Date de publication:
08 Feb 2020
Historique:
received: 27 10 2019
accepted: 24 01 2020
entrez: 10 2 2020
pubmed: 10 2 2020
medline: 2 6 2020
Statut: epublish

Résumé

In 2015, the first nationwide, multicenter Multiple Sclerosis (MS) registry was initiated in the Kingdom of Saudi Arabia (KSA) mainly with an objective to describe current epidemiology, disease patterns, and clinical characteristics of MS in Saudi Arabia. This article aimed to report initial findings of the registry and regional prevalence of MS. In 2015, a national MS registry was launched in KSA to register all MS patient with confirmed diagnosis according to the 2010 McDonald Criteria. The registry aimed to identify and recruit all healthcare facilities treating MS patients in the Kingdom, and collect data such as demographics, clinical characteristics (disease onset, diagnosis, presentation of symptoms at onset, disease course, relapse rate, and disability measures), family history, and treatments. All the included sites have obtained IRB/EC approvals for participating in the registry. Currently, the registry includes 20 hospitals from different regions across the Kingdom. The Projected prevalence was calculated based on the assumption that the number of diagnosed MS cases in participating hospitals (in each region) is similar to the number of cases in remaining nonparticipant hospitals in the same region. As of September 2018, the registry has included 20 hospitals from the different regions across the Kingdom and has collected comprehensive data on 2516 patients from those hospitals, with median age 32 (Range: 11-63) and 66.5% being females. The reported prevalence of MS for those hospitals was estimated to be 7.70/100,000 population and 11.80/100,000 Saudi nationals. Based on the assumption made earlier, we projected the prevalence for each region and for the country as a whole. The overall prevalence of MS at the country level was reported to be 40.40/100,000 total population and 61.95/100,000 Saudi nationals. Around 3 out of every 4 patients (77.5%) were 40 years of age or younger. Female to male ratio was 2:1. The prevalence was higher among females, young and educated individuals across all five regions of Saudi Arabia. The prevalence of MS has significantly increased in Saudi Arabia but is still much lower than that in the western and other neighboring countries like Kuwait, Qatar, and the UAE. However, compared to the past rates, Saudi Arabia's projected prevalence of MS through this national study is 40.40/100,000 population, putting the Kingdom above the low risk zone as per Kurtzke classification. The projected prevalence was estimated to be much higher among Saudi nationals (61.95/100,000 Saudi-nationals). The prevalence was higher among female, younger and educated individuals. Further studies are needed to assess the risk factors associated with increased prevalence in Saudi Arabia.

Sections du résumé

BACKGROUND BACKGROUND
In 2015, the first nationwide, multicenter Multiple Sclerosis (MS) registry was initiated in the Kingdom of Saudi Arabia (KSA) mainly with an objective to describe current epidemiology, disease patterns, and clinical characteristics of MS in Saudi Arabia. This article aimed to report initial findings of the registry and regional prevalence of MS.
METHOD METHODS
In 2015, a national MS registry was launched in KSA to register all MS patient with confirmed diagnosis according to the 2010 McDonald Criteria. The registry aimed to identify and recruit all healthcare facilities treating MS patients in the Kingdom, and collect data such as demographics, clinical characteristics (disease onset, diagnosis, presentation of symptoms at onset, disease course, relapse rate, and disability measures), family history, and treatments. All the included sites have obtained IRB/EC approvals for participating in the registry. Currently, the registry includes 20 hospitals from different regions across the Kingdom. The Projected prevalence was calculated based on the assumption that the number of diagnosed MS cases in participating hospitals (in each region) is similar to the number of cases in remaining nonparticipant hospitals in the same region.
RESULTS RESULTS
As of September 2018, the registry has included 20 hospitals from the different regions across the Kingdom and has collected comprehensive data on 2516 patients from those hospitals, with median age 32 (Range: 11-63) and 66.5% being females. The reported prevalence of MS for those hospitals was estimated to be 7.70/100,000 population and 11.80/100,000 Saudi nationals. Based on the assumption made earlier, we projected the prevalence for each region and for the country as a whole. The overall prevalence of MS at the country level was reported to be 40.40/100,000 total population and 61.95/100,000 Saudi nationals. Around 3 out of every 4 patients (77.5%) were 40 years of age or younger. Female to male ratio was 2:1. The prevalence was higher among females, young and educated individuals across all five regions of Saudi Arabia.
CONCLUSION CONCLUSIONS
The prevalence of MS has significantly increased in Saudi Arabia but is still much lower than that in the western and other neighboring countries like Kuwait, Qatar, and the UAE. However, compared to the past rates, Saudi Arabia's projected prevalence of MS through this national study is 40.40/100,000 population, putting the Kingdom above the low risk zone as per Kurtzke classification. The projected prevalence was estimated to be much higher among Saudi nationals (61.95/100,000 Saudi-nationals). The prevalence was higher among female, younger and educated individuals. Further studies are needed to assess the risk factors associated with increased prevalence in Saudi Arabia.

Identifiants

pubmed: 32035478
doi: 10.1186/s12883-020-1629-3
pii: 10.1186/s12883-020-1629-3
pmc: PMC7007659
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

49

Subventions

Organisme : King Abdulaziz City for Science and Technology (KACST)
ID : grant # AT-34-438

Références

Neuropsychiatr Dis Treat. 2017 Jul 18;13:1895-1903
pubmed: 28765711
Mult Scler Relat Disord. 2019 Jul;32:74-76
pubmed: 31055174
Eur J Neurol. 2013 Apr;20(4):697-703
pubmed: 23279712
Mult Scler Relat Disord. 2016 Sep;9:73-9
pubmed: 27645349
Mult Scler. 2013 May;19(6):816-9
pubmed: 22968545
J Neurol. 2008 Dec;255 Suppl 6:2-6
pubmed: 19300953
Front Neurol. 2018 Mar 29;9:201
pubmed: 29651272
Semin Neurol. 2016 Apr;36(2):103-14
pubmed: 27116717
Lancet Neurol. 2010 May;9(5):520-32
pubmed: 20398859
Rev Neurol. 2016 May 1;62(9):396-402
pubmed: 27113063
Lancet Neurol. 2011 Nov;10(11):953-4
pubmed: 22014431
Neuroepidemiology. 2015;44(4):232-44
pubmed: 26088327
Neurology. 2014 Sep 9;83(11):1022-4
pubmed: 25200713
Lab Invest. 2001 Mar;81(3):263-81
pubmed: 11310820
Neuropsychol Rev. 2019 Sep;29(3):259-269
pubmed: 31102028
BMC Neurol. 2018 Jun 19;18(1):86
pubmed: 29914402
J Neurol. 2013 Dec;260(12):2959-63
pubmed: 23504049
PLoS One. 2016 Dec 9;11(12):e0167556
pubmed: 27936086
Lancet Neurol. 2019 Mar;18(3):269-285
pubmed: 30679040
J Neurol. 2015 Oct;262(10):2352-63
pubmed: 26205633

Auteurs

Mohammed AlJumah (M)

King Fahd Medical City (KFMC), MOH, Riyadh, Saudi Arabia. jumahm@gmail.com.

R Bunyan (R)

King Fahd Specialist Hospital (KFSH)-Dammam, Dammam, Saudi Arabia.

H Al Otaibi (H)

King Fahd General Hospital-Jeddah, Jeddah, Saudi Arabia.

G Al Towaijri (G)

King Fahd Medical City (KFMC), MOH, Riyadh, Saudi Arabia.

A Karim (A)

King Fahd General Hospital-Al-Madinah, Riyadh, Saudi Arabia.

Y Al Malik (Y)

King Abdulaziz Medical City (National Guard Health Affairs)-Riyadh, Riyadh, Saudi Arabia.
King Saud bin Abdulaziz University For Health Sciences, Riyadh, Saudi Arabia.

M Kalakatawi (M)

Nour Specialized Hospital, Makkah, Saudi Arabia.

S Alrajeh (S)

Dr. Sulaiman Al Habib Hospital-Olaya Branch, Riyadh, Saudi Arabia.

M Al Mejally (M)

Heraa General Hospital, Makkah, Saudi Arabia.

H Algahtani (H)

King Abdul-Aziz Medical City (National Guard Health Affairs), Jeddah, Saudi Arabia.

A Almubarak (A)

Qatif Central Hospital, Qatif, Saudi Arabia.

E Cupler (E)

King Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia.

S Alawi (S)

Prince Sultan Military Medical City, Riyadh, Saudi Arabia.

S Qureshi (S)

Johns Hopkins Aramco Healthcare Company (JHAH), Dhahran, Saudi Arabia.

S Nahrir (S)

King Saud Medical City, Riyadh, Saudi Arabia.

A Almalki (A)

King Abdul-Aziz Hospital and Oncology Center, Jeddah, Saudi Arabia.

A Alhazzani (A)

King Saud University, Riyadh, Saudi Arabia.

I Althubaiti (I)

King Fahad Military Medical Complex, Dhahran, Saudi Arabia.

N Alzahrani (N)

King Fahd General Hospital, Baha, Saudi Arabia.

E Mohamednour (E)

King Fahad Specialist Hospital, Dammam, Qassim, Saudi Arabia.

J Saeedi (J)

King Abdullah Bin Abdulaziz University Hospital, Riyadh, Saudi Arabia.

S Ishak (S)

Itkan Health Consulting, Riyadh, Saudi Arabia.

H Almudaiheem (H)

Ministry of Health, Deputyship of Therapeutic Affairs, Riyadh, Saudi Arabia.

A El-Metwally (A)

King Saud bin Abdulaziz University For Health Sciences, Riyadh, Saudi Arabia.

A Al-Jedai (A)

Ministry of Health, Deputyship of Therapeutic Affairs, Riyadh, Saudi Arabia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH